Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Protagonist Therapeutics, Inc. - Common Stock
(NQ:
PTGX
)
101.40
+2.89 (+2.93%)
Streaming Delayed Price
Updated: 2:56 PM EDT, Apr 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Protagonist Therapeutics, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
March 18, 2024
Via
ACCESSWIRE
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
March 11, 2024
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
March 06, 2024
Via
ACCESSWIRE
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 27, 2024
Via
ACCESSWIRE
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
February 21, 2024
Via
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Awards
February 20, 2024
Via
ACCESSWIRE
The Latest Analyst Ratings for Protagonist Therapeutics
↗
November 03, 2023
Via
Benzinga
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 02, 2023
Via
ACCESSWIRE
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
October 09, 2023
Via
ACCESSWIRE
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
February 07, 2024
Via
ACCESSWIRE
Why Is Japanese Drugmaker Takeda Stock Trading Lower Today?
↗
February 01, 2024
Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration deal for rusfertide. Fiscal year 2023 guidance reiterated.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
January 31, 2024
Via
Benzinga
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
January 31, 2024
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024
January 29, 2024
Via
ACCESSWIRE
What 6 Analyst Ratings Have To Say About Protagonist Therapeutics
↗
September 25, 2023
Via
Benzinga
Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
Via
ACCESSWIRE
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
December 13, 2023
Via
ACCESSWIRE
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
December 12, 2023
Via
ACCESSWIRE
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
November 27, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Awards
November 16, 2023
Via
ACCESSWIRE
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
↗
November 16, 2023
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.
Via
The Motley Fool
Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)
November 09, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting
November 02, 2023
Via
ACCESSWIRE
Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis
November 01, 2023
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
November 01, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors
October 30, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
October 03, 2023
Via
ACCESSWIRE
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
September 22, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,...
Via
FinancialNewsMedia
Protagonist Therapeutics to Present at Upcoming Investor Conferences
September 05, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
August 16, 2023
Via
ACCESSWIRE
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
